sonidegib (Odomzo)

  • Pharmacy Author:
    Omudhome Ogbru, PharmD

    Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.

  • Medical and Pharmacy Editor: Jay W. Marks, MD
    Jay W. Marks, MD

    Jay W. Marks, MD

    Jay W. Marks, MD, is a board-certified internist and gastroenterologist. He graduated from Yale University School of Medicine and trained in internal medicine and gastroenterology at UCLA/Cedars-Sinai Medical Center in Los Angeles.

GENERIC NAME: sonidegib

BRAND NAME: Odomzo

DRUG CLASS AND MECHANISM: Odomzo (sonidegib) is an oral medication used to treat a type of skin cancer called basal cell carcinoma. Sonidegib is an inhibitor of the hedgehog biological signaling pathway, a pathway that promotes the growth of both normal and cancer cells. Sonidegib binds to and inhibits smoothened, a protein involved in hedgehog signaling. Inhibiting smoothened disrupts cell signaling and growth of cancer cells. Sonidegib was approved by the FDA in July, 2015.

PRESCRIBED FOR: Sonidegib is an oral medication used to treat adults with basal cell carcinoma that has recurred following surgery or radiation treatment. It also is used for treating basal cell carcinoma that cannot be treated with surgery or radiation.

SIDE EFFECTS WARNING:

Sonidegib can cause harm to the fetus and should not be used during pregnancy.

  • A negative pregnancy test is required before starting sonidegib.
  • Females of child bearing potential are advised to use effective forms of birth control (contraception) during treatment and for least 20 months after stopping sonidegib.
  • Female patients exposed to sonidegib during pregnancy should report her pregnancy to Novartis Pharmaceuticals Corporation by calling 1-888-669-6682.
  • Male patients with female partners are advised to use condoms, even after a vasectomy, during treatment and for at least 8 months after stopping sonidegib.
  • Patients should not donate blood or blood products while taking sonidegib and for at least 20 months after stopping because donated blood and blood products may be given to pregnant females or females who can become pregnant, and cause harm to the fetus.

Sonidegib may cause musculoskeletal side effects. Blood creatine kinase (CK) and creatinine levels should be obtained prior to treatment, periodically during treatment, and as needed.

Medically Reviewed by a Doctor on 8/24/2015

Quick GuidePancreatic Cancer Symptoms, Causes, and Treatment

Pancreatic Cancer Symptoms, Causes, and Treatment
FDA Logo

Report Problems to the Food and Drug Administration

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

RxList Logo

Need help identifying pills and medications?

Use the pill identifier tool on RxList.

Subscribe to MedicineNet's Cancer Report Newsletter

By clicking Submit, I agree to the MedicineNet's Terms & Conditions & Privacy Policy and understand that I may opt out of MedicineNet's subscriptions at any time.

Health Solutions From Our Sponsors